Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
|Articles|September 5, 2014
How to create a dry eye center
In this video, Dr. Scott Schachter discusses creating a dry eye center.
Advertisement
In his first installment for his Optometry Times blog, the Schachter Factor, Dr. Scott Schachter discusses creating a dry eye center in your practice. Questions or comments? E-mail Dr. Schachter at scotts.gm@gmail.com.
Having trouble viewing this video?
Advertisement
Related to this article
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
IDOC's 2025 benchmarks from 175-plus independent OD practices put median practice net at 31% of revenue as variable costs fell for the first time since tracking began.
Maria Sampalis, OD, discusses her implementation of the EHR software Barti in her practice.
Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
4
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
5